Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOW: Glatiramer Acetate 20mg/0.5ml in RRMS
NCT01578785Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2012
- Primary completion
- Oct 2012
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Glatiramer Acetate with Placebo (2 arms). Primary endpoint: Annualized Relapse Rate at 12 months. Started Mar 2012; status: terminated.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01578785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01578785.